PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain

International Journal of Neuropsychopharmacology

Volumn 11, Issue 2, 2008, Pages 163-171

  Nordstrom, Anna Lena ^a,c   Mansson, Mattias ^a   Jovanovic, Hristina ^a   Karlsson, Per ^a   Halldin, Christer ^a   Farde, Lars ^a   Vanover, Kimberly E ^b   Hacksell, Uli ^b   Brann, Mark R ^b   Davis, Robert E ^b   Weiner, David M ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ACADIA PHARMACEUTICALS INC   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 HT2A receptor; ACP 103; Inverse agonist; PET

Indexed keywords

3 METHYLSPIPERONE C 11; PIMAVANSERIN; SEROTONIN 2A ANTAGONIST;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSLEXIA; FATIGUE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BRAIN; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; HUMANS; MALE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT2A; SPIPERONE; UREA;

EID: 38949160001     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145707007869     Document Type: Article

References (40)

1. Andree B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F, Halldin C, Farde L (1998). Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. Journal of Clinical Psychopharmacology 18, 317-323.
2. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM (1992). Do central antiadrenergic actions contribute to the atypical properties of clozapine? British Journal of Psychiatry (Suppl.) 12-16.
3. Barnes TR (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
4. Baron JC, Martinot JL, Cambon H, Boulenger JP, Poirier MF, Caillard V, Blin J, Huret JD, Loc'h C, Maziere B (1989). Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berlin), 463-472.
5. Bergstrom M, Boethius J, Eriksson L, Greitz T, Ribbe T, Widen L (1981). Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. Journal of Computer Assisted Tomography 5, 136-141.
6. Birkmayer W, Danielczyk W, Neumayer E, Riederer P (1974). Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings. Journal of Neural Transmission 35, 93-116.
7. Cambon H, Baron JC, Boulenger JP, Loc'h C, Zarifian E, Maziere B (1987). In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans. British Journal of Psychiatry 151, 824-830.
8. Carlsson A, Waters N, Carlsson ML (1999). Neurotransmitter interactions in schizophrenia-therapeutic implications. European Archives of Psychiatry and Clinical Neuroscience 249 (Suppl. 4), 37-43.
9. Farde L, Wiesel FA, Halldin C, Sedvall G (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry 45, 71-76.
10. 3H-N-methylspiperone to dopamine and serotonin receptors. Life Sciences 40, 987-995.
11. French Clozapine Parkinson Study Group (1999). Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 353, 2041-2042.
12. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. American Journal of Psychiatry 157, 514-520.
13. Leysen JE, Niemegeers CJ, Tollenaere JP, Laduron PM (1978). Serotonergic component of neuroleptic receptors. Nature 272, 168-171.
14. 3H]raclopride. Proceedings of the National Academy of Sciences USA 86, 6412-6416.
15. Meltzer HY, Arvanitis L, Bauer D, Rein W (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry 161, 975-984.
16. Meltzer HY, Bastani B, Ramirez L, Matsubara S (1989). Clozapine: new research on efficacy and mechanism of action. European Archives of Psychiatry and Neurological Science 238, 332-339.
17. 11C]methionine. Journal of Labelled Compounds and Radiopharmaceuticals XLI, 831-841.
18. Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verriele L, Carpentier N, Millan MJ (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 303, 815-822.
19. Nordstrom AL, Farde L (1998). Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. Journal of Clinical Psychopharmacology 18, 305-310.
20. Nordstrom AL, Farde L, Halldin C (1993a). High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berlin) 110, 365-367.
21. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995). D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. American Journal of Psychiatry 152, 1444-1449.
22. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993b). Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biological Psychiatry 33, 227-235.
23. Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B (1993). 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berlin) 110, 265-272.
24. Nyberg S, Farde L, Halldin C (1997). A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16, 1-7.
25. Nyberg S, Dencker SJ, Malm U, Dahl ML, Svenson JO, Halldin C, Naskashima Y, Farde L (1998). D(2)- and 5-HT(2) receptor occupancy in high-dose neuroleptic-treated patients. International Journal of Neuropsychopharmcology 1, 95-101.
26. Parkinson Study Group (1999). Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. New England Journal of Medicine 340, 757-763.
27. Pazos A, Probst A, Palacios JM (1987). Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21, 123-139.
28. Potkin SG, Shipley J, Bera RB, Carreon D, Fallon J, Alva G, Keator D (2001). Clinical and PET effects of M100907, a selective 5-HT-2A receptor antagonist. Schizophrenia Research 49 (Suppl. 1), 242.
29. Roberts C (2006). ACP-103, a 5-HT2A receptor inverse agonist. Current Opinion in Investigational Drugs 7, 653-660.
30. Schotte A, Maloteaux JM, Laduron PM (1983). Characterization and regional distribution of serotonin S2-receptors in human brain. Brain Research 276, 231-235.
31. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica (Suppl.) 212, 11-19.
32. Smith M, Wolf AP, Brodie JD, Arnett CD, Barouche F, Shiue CY, Fowler JS, Russell JA, MacGregor RR, Wolkin A, et al. (1988). Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biological Psychiatry 23, 653-663.
33. Talvik-Lotfi M, Nyberg S, Nordström A-L, Ito H, Halldin C, Brunner F, Lars F (2000). High 5HT2A occupancy in MDL 100.907 treated patients demonstrated by PET. Psychopharmacology 148, 400-403.
34. Tamminga CA (2003). The science of antipsychotics: mechanistic insight. CNS Spectrums 8, 5-9.
35. Vanover K, Robbins-Weilert D, Wilbraham D, Mant T, van Kammen D, Davis R, Weiner D (In Press a). The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers. Journal of Clinical Pharmacology.
36. Vanover K, Robbins-Weilert D, Wilbraham D, Mant T, van Kammen D, Davis R, Weiner D (In Press b). Pharmacokinetics, tolerability and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers. Journal of Clinical Pharmacology.
37. Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, et al. (2006). Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)- N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)- dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. Journal of Pharmacology Experimental Therapy 317, 910-918.
38. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, et al. (2001). 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. Journal of Pharmacology Experimental Therapy 299, 268-276.
39. Weiner DM, Vanover KE, Brann MR, Meltzer HY, Davis RE (2003). Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics. Current Opinion in Investigational Drugs 4, 815-819.
40. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss WD (1994). The ECAT EXACT HR: performance of a new high resolution positron scanner. Journal of Computer Assisted Tomography 18, 110-118.